Below is a press release from Intermune, the company that makes Pirfenidone. They have essentially reviewed the various clinical trials going on, and decided that Pirfenidone is safe and well tolerated. That would pretty much go along with what we've observed in the HPS community as well. We have a few folks that have been on the drug since the late 90s and continue to do well. Of course, as a journalist, I do have to say consider the source - but at the same time, as someone in a Pirfenidone trial, it's good to know. Results of Comprehensive Safety Analysis of pirfenidone In IPF Patients Presented At European Respiratory Meeting - Analysis shows safety and tolerability of pirfenidone across four clinical trials - VIENNA, Sept. 14 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN ) today announced that the results of a comprehensive review of safety data from four clinical studies were presented at the 2009 European Respiratory Society Annual Congress in Vienna, Austria...
At Monday afternoon’s ATS President’s Symposium, NHLBI Director Elizabeth G. Nabel talked about how the federal economic stimulus package is changing the financial state of scientific research. Indeed the NIH issued a press release about several new grants to research pulmonary fibrosis. I posted that a few days ago. The only worry about this funding is that it's temporary. I hope those of us who advocate for scientific research funding don't get lazy with this temporary influx of dollars. Instead, I hope that the science that comes out of this funding push only helps to prove why we need for funding for medical research. This photo is from the ATS press room.
Comments